First Steps Toward a Treatment Strategy That Makes Cancer Cells Destroy Themselves

One of the most important oncogenesin cancer is MYC. However, despite years of research, an effective drug against MYC has not been developed. Recently, research into discovering growth pathwaysin MYC-dependent tumors had increased. In this context, a study published in July 2019 in Nature Cell Biology discovered a new pathway in MYC-dependent tumors. When the activity of the ATF4 protein in this pathway was inhibited, cancer cells were observed to destroy themselves. These findings could pave the way for effective cancer treatments. In addition, molecules that block the ATF4 protein were successfully developed.
Oncogenes: They arise when "proto-oncogenes," which normally regulate cell proliferation, lose their functions. Oncogenes cause cancer to progress aggressively.

MYC is one of the genes that normally control cell growth. When MYC undergoes a mutation , it promotes uncontrolled cell proliferation. Mutated MYC has been identified in many aggressive cancer types. So far, no drug against MYC has been developed. Researchers are therefore investigating treatment strategies that target MYC indirectly. This study discovered the weak spot of MYC-dependent tumors.
According to the research findings:
- In analyses of mouse models of MYC-dependent lymphoma and colorectal cancer, blocking the ATF4 protein was found to cause tumor cells to produce excessive amounts of the 4E-BP protein. This increase in the protein stopped tumor growth.
- Further analyses of human tumor samples showed high activity of the ATF4 and 4E-BP proteins in MYC-dependent cancers. This suggests that inhibiting ATF4 activity could be effective in human cancers.
What Does This Study Mean for Us?
- An alternative treatment strategy has been discovered for MYC-dependent tumors that could not previously be targeted with drugs.
- In MYC-dependent tumors, blocking a protein called ATF4 was found to cause tumor cells to destroy themselves.
- Further studies are investigating what side effects blocking the ATF4 protein might cause in humans. It is essential to emphasize that this research is still at the laboratory stage.
Sources
ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression.
Nature Cell Biology, 01 July 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.